Aptorum Group Limited (NASDAQ:APM) Short Interest Update

Aptorum Group Limited (NASDAQ:APM) was the recipient of a large growth in short interest in the month of February. As of February 27th, there was short interest totaling 11,553 shares, a growth of 14.8% from the February 12th total of 10,060 shares. Approximately 0.5% of the company’s shares are short sold. Based on an average daily volume of 12,784 shares, the short-interest ratio is currently 0.9 days. Based on an average daily volume of 12,784 shares, the short-interest ratio is currently 0.9 days. Approximately 0.5% of the company’s shares are short sold.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Aptorum Group in a research report on Monday, December 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has an average rating of “Sell”.

Aptorum Group Trading Down 0.8%

Shares of NASDAQ:APM opened at $0.79 on Tuesday. Aptorum Group has a 1 year low of $0.65 and a 1 year high of $4.47. The firm’s 50-day moving average is $0.88 and its two-hundred day moving average is $1.31.

Aptorum Group Company Profile

Aptorum Group Ltd. (NASDAQ: APM) is a global biopharmaceutical company incorporated under the laws of the Cayman Islands and headquartered in Hong Kong. Since its Nasdaq listing in 2018, the company has focused on the discovery, development and commercialization of novel therapeutics and diagnostic products. Aptorum’s research efforts are aimed at addressing unmet medical needs across oncology, metabolic disorders, infectious diseases and neurological conditions.

The company’s diversified pipeline includes both small-molecule and biologic drug candidates, as well as companion diagnostic tools.